Competitors don't stop drugs from getting approved. Shitty data does.
Nobody is trying to bankrupt the company. When you screw your only institutional investor with deep pockets, Woodford, you are gonna have a hard time getting non-crappy financing. Any legit financier is paying a team of statisticians and doctors to go over the data just like those who reported all of the problems with this trial, and those guys are going to see the exact same problems and tell the financier paying them big bucks to stay away.
News 
Market Data 
Discover 
